DSIP is a nine-amino-acid neuropeptide isolated in 1977, and its name records the experiment that found it rather than a confirmed function. Decades of follow-up work have not established that it reliably induces delta sleep in humans, no receptor or definitive mechanism has ever been identified, and no regulator has approved it for any indication. It reaches buyers through the research-chemical channel, which is where most of the practical concern attached to the peptide sits.
DSIP was characterized in 1977 as a nonapeptide and remains unapproved by the FDA and the EMA for any indication, with no cloned receptor and no large randomized trial supporting the delta-sleep effect its name promises.
The name came from a bioassay, not from a pathway, and that distinction carries most of the confusion still attached to the molecule. Monnier and Schoenenberger recovered the active fraction from the blood of rabbits pushed into delta-wave sleep by electrical stimulation, then watched recipient animals show the same activity. Everything downstream of that clean result has resisted explanation.
The 1977 work gave DSIP a sequence and a molecular weight but no receptor and no settled mechanism, and the peptide's plasma half-life of minutes and poor blood-brain barrier penetration leave the route from an injected dose to a central effect unmapped.
Very little, and the thinness is the finding rather than a gap waiting to be filled. The human sleep literature runs to a handful of studies concentrated in the early and mid 1980s, most enrolling fewer than twenty subjects, several of them open-label, and almost none replicated by an independent group. Weighed against a real sleep problem, that is the whole picture, not a caveat attached to it.
No large randomized placebo-controlled trial of DSIP for insomnia has ever been published, and several of the small 1980s studies that used polysomnography failed to demonstrate the increase in delta-wave sleep the peptide is named for.
Once the sleep results proved hard to reproduce, investigators pointed the peptide at other indications, and the literature widened without deepening. Sleep, pain, withdrawal, stress hormones, oxidation, and tumor growth have each drawn a study or two, on a few dozen subjects per claim. That breadth is the signature of an underpowered literature rather than a pharmacological Swiss army knife.
Every non-sleep indication studied for DSIP, from opioid and alcohol withdrawal to chronic pain, cortisol regulation, and antitumor activity, rests on the same small, old, largely unreplicated studies that failed to settle the sleep question.
The FDA has never approved DSIP for any indication and no DSIP product has been the subject of an approved New Drug Application, which settles most of the rest. It isn't a scheduled controlled substance either, so it sits where peptides generally sit, governed as an unapproved new drug rather than by criminal drug law. That leaves the research-chemical channel, where the phrase for research use only is a seller's disclaimer rather than an approval or a safe harbor.
DSIP is not FDA-approved and is not on the 503A bulks list, which keeps the compounding route closed while the Pharmacy Compounding Advisory Committee is scheduled to weigh emideltide for listing on July 24, 2026, against evaluated uses in opioid withdrawal, chronic insomnia, and narcolepsy.
Published studies described DSIP as well tolerated, and that phrase carries less than it appears to. Well tolerated across a few dozen subjects, in short exposures, decades ago, under research conditions, describes the absence of a safety profile rather than the presence of one. The larger hazards in practice attach to the channel, not to the molecule.
No long-term human safety data, carcinogenicity or reproductive toxicology package, or drug interaction study exists for DSIP, so its documented risks are those of injecting an unverified gray-market substance rather than anything a package insert would list.
No validated dosing protocol for DSIP exists, and that frames everything below, because describing what a 1984 study did is not the same as describing what should be done. The pharmacokinetics make the timing question genuinely strange: a compound cleared from plasma in minutes is a poor candidate for the durable effects some of those studies reported, which is why researchers proposed a downstream cascade nobody has since demonstrated.
Published human DSIP studies used parenteral dosing clustered around 25 to 30 nanomoles per kilogram, roughly one and a half milligrams per dose, given in short daily courses, and no validated protocol has ever been established from that work.
Placed beside anything carrying a regulatory file, DSIP is not a close comparison. Approved insomnia medications, whether benzodiazepine receptor agonists, dual orexin receptor antagonists, or melatonin receptor agonists, each bring thousands of randomized subjects, published polysomnographic outcomes, and post-marketing surveillance, against a few dozen 1980s subjects and an unconfirmed mechanism. Cognitive behavioral therapy for insomnia sits further ahead still, as the guideline-recommended first-line treatment that outperforms medication on durability without pharmacological risk.
| Criteria | Approved insomnia medications | DSIP |
|---|---|---|
| Trial base | Thousands of randomized subjects | A few dozen subjects, mostly 1980s |
| Objective endpoints | Published polysomnographic outcomes | Inconsistent; namesake delta effect unconfirmed |
| Mechanism | Characterized receptor targets | No receptor cloned |
| Oversight | Post-marketing surveillance, known interactions | None |
| Availability | Prescription | Research-chemical channel |
Approved insomnia medications and cognitive behavioral therapy for insomnia each rest on thousands of randomized subjects and guideline recognition, while DSIP has no adequately powered placebo-controlled trial, no characterized mechanism, and no manufacturing standard.
Every claim about what DSIP does presumes the vial contains DSIP, and that presumption is the weakest link in the chain. Research-chemical peptides are typically synthesized by contract manufacturers, frequently overseas, then resold by intermediaries who repackage, relabel, and market them online, and the reseller usually cannot say with authority what happened upstream.
Independent analyses of gray-market peptides have repeatedly found vials whose identity, purity, or stated quantity diverged from the label, so the research-use-only channel that supplies DSIP verifies nothing about the contents of a given vial.
Priced by the vial, DSIP is inexpensive relative to the attention it attracts, with research-chemical vendors generally listing lyophilized 5 milligram vials somewhere between twenty and sixty dollars and multi-vial discounts pushing the effective unit price lower. Synthesis of a nine-amino-acid peptide is modest at scale, so the wide vendor-to-vendor spread on an identical stated product tracks margin, marketing, packaging, and whether independent testing was actually paid for, not anything verified about the contents. A low price is informative in the wrong direction, since lot testing costs real money and a vendor competing on price alone has an obvious reason to skip it.
| Criteria | DSIP via research-chemical vendor | Prescription generic or CBT-I |
|---|---|---|
| Advertised cost | $20 to $60 per 5 mg vial | Real-world costs competitive with a peptide habit |
| Add-on costs | Bacteriostatic water, syringes, swabs, cold storage | None beyond the treatment |
| Independent lot testing | Buyer's expense, rarely paid for | Included in cGMP release testing |
| Evidence included | A few dozen 1980s subjects | Trial base and guideline recognition |
| Oversight included | None | Clinician and post-marketing surveillance |
DSIP lists at roughly twenty to sixty dollars per 5 milligram vial, a figure that excludes bacteriostatic water, injection supplies, cold storage, and the independent lot testing almost no buyer pays for, which is what separates inexpensive from cheap.
Educational use only. This article describes what the published scientific and clinical literature reports about DSIP. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
